Impact on survival of severe immuno-related adverse events in deficient mismatch repair/microsatellite instable-high digestive cancers treated with immunotherapy
David Tougeron, Charles Kauffmann, Margherita Ambrosini, Olayide Boussari, Sara Lonardi, Frank A Sinicrope, Marwan Fakih, Michael J Overman, Elena Elez, Anthony Turpin, Marie Decraecker, Antoine Hollebecque, Simon Pernot, Thibault Mazard, Marie Dutherage, Romain Cohen, Francesco Sclafani, Mohamed Ben Abdelghani, Thomas Aparicio, Clélia Coutzac, Vincent Hautefeuille, Marie Muller, Chiara Cremolini, Rosine Guimbaud, Julien Taieb, Filippo Pietrantonio, Raphael Olivier, Emily Alouani · 2026
Read Impact on survival of severe immuno-related adverse events in deficient mismatch repair/microsatellite instable-high digestive cancers treated with immunotherapy by David Tougeron, Charles Kauffmann, Margherita Ambrosini, Olayide Boussari, Sara Lonardi, Frank A Sinicrope, Marwan Fakih, Michael J Overman, Elena Elez, Anthony Turpin, Marie Decraecker, Antoine Hollebecque, Simon Pernot, Thibault Mazard, Marie Dutherage, Romain Cohen, Francesco Sclafani, Mohamed Ben Abdelghani, Thomas Aparicio, Clélia Coutzac, Vincent Hautefeuille, Marie Muller, Chiara Cremolini, Rosine Guimbaud, Julien Taieb, Filippo Pietrantonio, Raphael Olivier, Emily Alouani (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13410918.txt.
Description
David Tougeron leads an international team asking in 2026 whether severe immune side effects during cancer immunotherapy link to better survival. The cancers studied carry a DNA repair fault that makes them respond well to checkpoint drugs. Those same drugs often inflame healthy organs, sometimes badly.
Records from 34 centers covered 1,175 patients with digestive cancers. About a tenth suffered severe immune side effects, most often in gut or liver, arising a median of about four months into treatment. Combination drug regimens raised that risk. Patients with severe events answered treatment more often than others. Restarting the drugs after such an event brought the inflammation back in over half of cases, a caution for clinics.
Catalog record
| CREATOR | David Tougeron, Charles Kauffmann, Margherita Ambrosini, Olayide Boussari, Sara Lonardi, Frank A Sinicrope, Marwan Fakih, Michael J Overman, Elena Elez, Anthony Turpin, Marie Decraecker, Antoine Hollebecque, Simon Pernot, Thibault Mazard, Marie Dutherage, Romain Cohen, Francesco Sclafani, Mohamed Ben Abdelghani, Thomas Aparicio, Clélia Coutzac, Vincent Hautefeuille, Marie Muller, Chiara Cremolini, Rosine Guimbaud, Julien Taieb, Filippo Pietrantonio, Raphael Olivier, Emily Alouani |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 47511 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |